Preoperative [68Ga]Ga-FAPI-04 PET for evaluating pathological complete response to neoadjuvant therapy in gastrointestinal adenocarcinoma patients
[<sup>68</sup>Ga]Ga-FAPI-04 PET shows promise in predicting pCR among patients with gastrointestinal adenocarcinomas following NAT. FAPI-PTV derived from [<sup>68</sup>Ga]Ga-FAPI-04 PET may provide an effective clinical tool for guiding further treatment.
Authors
- Zhaoguo Lin (ORCID: https://orcid.org/0000-0002-1545-9725)
- Ranran Chen (ORCID: https://orcid.org/0000-0002-6743-9216)
- Yongkang Gai (ORCID: https://orcid.org/0000-0001-6766-5240)
- Xiaoli Lan (ORCID: https://orcid.org/0000-0002-7263-7399)
- Chunxia Qin (ORCID: https://orcid.org/0000-0002-0291-4418)
- Feng Yuan (ORCID: https://orcid.org/0000-0002-5358-2222)
- Xiao Zhang (ORCID: https://orcid.org/0009-0002-9537-8120)
Institutions
- Fujian Medical University (CN)
- Wuhan Union Hospital (CN)
- Union Hospital (CN)
- Hubei University (CN)
- Wuhan Institute of Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1687329
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China